SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Precipio, Inc. (PRPO) (CIK 0001043961) (PRPO) — Jul 2, 2020

Precipio, Inc. (PRPO) (CIK 0001043961)
Date: July 2, 2020 · CIK: 0001043961 · Accession: 0000000000-20-005963

AI Filing Summary & Sentiment

File numbers found in text: 333-239506

Date
July 2, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Precipio, Inc. (PRPO) (CIK 0001043961)

Letter

United States securities and exchange commission logo July 2, 2020 Ilan Danieli Chief Executive Officer Precipio, Inc. 4 Science Park New Haven, Connecticut 06511 Re:Precipio, Inc. Registration Statement on Form S-1 Filed June 26, 2020 File No. 333-239506 Dear Mr. Danieli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Deanna Virginio at 202-551-4530 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas A. Rose, Esq.

Show Raw Text
United States securities and exchange commission logo
July 2, 2020
Ilan Danieli
Chief Executive Officer
Precipio, Inc.
4 Science Park
New Haven, Connecticut 06511
Re:Precipio, Inc.
Registration Statement on Form S-1
Filed June 26, 2020
File No. 333-239506
Dear Mr. Danieli:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Deanna Virginio at 202-551-4530 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Thomas A. Rose, Esq.